Update of Recommendations on First- and Second-line Antiretroviral Regimens. WHO. (2019)

immage

These guidelines provide further reassurance of DTG as the preferred antiretroviral (ARV) drug in first- and second-line regimens due to the declining estimate of neural tube defect risk and observed efficacy. This reassurance comes at a time when pretreatment resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTI) is increasing in low- and middle-income countries, creating demand for access to alternative non-NNRTI ARV drugs.

 

Keywords: HIV, ARV, treatment, drugs, access

 

Download Publication

  Previous Next  

Data Dashboard
database
Highlighted publications
https://aidsdatahub.org/sites/default/files/highlight-reference/document/ESCAP_Asia_and_the_Pacific_SDG_Progress_Report_2020.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/Myanmar_Progress_Report_2018.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/Cambodia_National_and_Subnational_HIV_Estimates_and_Projections_2019.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/Cambodia_NASA_Report_2016-2017.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_TB_Global_Report_2019.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS-Global-AIDS-Update_Asia-Pacific_2019.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS-changing-laws-that-discriminate_2019.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/PNG_HIV_National_Strategic_Information_2018-22.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/PNG_National_STI_and_HIV_Strategy.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS-young-peoples-participation-in-community-based-responses-to-hiv_2019.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/UNODC_factsheet_Ending_AIDS_by_2030_for_people_and_with_PUD_2018.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/HRI-women-harm-reduction-2018.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Elective_C-section_should_not_be_routinely_recommended_to_WLHIV_2018.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Guideline_on_digital_interventions_for_health_system_strengthening_2019.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Progress_report_on_HIV_viral_hepatitis_and_STI_2019.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_HIV_UHC_Guide_Civil_Society_2019.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/NSACP_Sri_Lanka_Annual_Report_2018.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_HIV-related-travel-restrictions-explainer_2019.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/HIV-and-the-Law-supplement-2018.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/Myanmar_IBBS_and_Population_size_estimates_among_FSW_2015.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/Nepal_National_Community_Led_HIV_Testing_Guidelines_2018.pdf
Calendar of events
Mar
1
(1 Mar - 1 Mar)
Mar
3
Mar
8
(8 Mar - 8 Mar)